Elanco Animal Health Incorporated (ELAN)
Stock Price Chart
Key Info
| Market Cap | 14.58B |
| Revenue (ttm) | 2.80B |
| Net Income (ttm) | -101.80M |
| Shares Out | 471.85M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | 31.15 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 19, 2020 |
| Last Price | $30.91 |
| Previous Close | $31.54 |
| Change ($) | -0.63 |
| Change (%) | -2.00% |
| Day's Open | 31.62 |
| Day's Range | 30.56 - 31.63 |
| Day's Volume | 3,856,456 |
| 52-Week Range | 15.17 - 34.09 |
More Stats
| Market Cap | 14.58B |
| Enterprise Value | 15.24B |
| Earnings Date (est) | Nov 6, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 471.85M |
| Float | 397.48M |
| EPS (basic) | -0.25 |
| EPS (diluted) | -0.26 |
| FCF / Share | 0.35 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 0.99% |
| Payout Ratio | n/a |
| Shares Short | 26.26M |
| Short Ratio | 6.57 |
| Short % of Float | 6.61% |
| Beta | 1.04 |
| PE Ratio | n/a |
| Forward PE | 31.15 |
| P/FCF Ratio | 101.42 |
| PS Ratio | 5.20 |
| PB Ratio | 2.26 |
| Revenue | 2.80B |
| Operating Income | -130.90M |
| Net Income | -101.80M |
| Free Cash Flow | 143.80M |
| Net Cash | -654.50M |
| Net Cash / Share | -1.39 |
| Gross Margin | 57.12% |
| Operating Margin | -4.67% |
| Profit Margin | -3.60% |
| FCF Margin | 5.13% |
| ROA | 1.43% |
| ROE | -1.71% |
| ROIC | -1.80% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | 3,071 | 3,067 | 2,889 | 2,914 | 2,909 |
| Revenue Growth | 0.14% | 6.15% | -0.84% | 0.15% | - |
| Gross Profit | 1,601 | 1,493 | 1,395 | 1,505 | 1,375 |
| Operating Income | 157 | 144 | -233 | -22.40 | -258 |
| Net Income | 67.90 | 86.50 | -311 | -47.90 | -211 |
| Shares Outstanding | 369 | 314 | 293 | 293 | - |
| Earnings Per Share | 0.18 | 0.28 | -1.06 | -0.16 | - |
| EPS Growth | -35.71% | - | - | - | - |
| Operating Cash Flow | 224 | 487 | 174 | 156 | 6.60 |
| Capital Expenditures | -197 | -127 | -79.50 | -103 | -79.80 |
| Free Cash Flow | 27.00 | 360 | 94.30 | 53.00 | -73.20 |
| Cash & Equivalents | 345 | 678 | 323 | 259 | - |
| Total Debt | 2,355 | 2,472 | - | - | - |
| Net Cash / Debt | -2,010 | -1,795 | 323 | 259 | - |
| Assets | 8,986 | 8,957 | 8,940 | 8,100 | - |
| Liabilities | 3,439 | 3,759 | 1,160 | 1,072 | - |
| Book Value | 5,547 | 5,198 | 7,780 | 7,028 | - |
Company Profile
Company Details
| Full Name | Elanco Animal Health Incorporated |
| Country | United States |
| Employees | 6,000 |
| CEO | Jeffrey N. Simmons |
Stock Information
| Ticker Symbol | ELAN |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: ELAN |
| IPO Date | September 20, 2018 |
Description
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for companion and food animals. It offers companion animal disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production. The company sells its products to third-party distributors; veterinarians; and food animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. The company has a research and development collaboration with AgBiome, Inc. to develop nutritional health products for swine; and strategic alliance with the Purdue University and Purdue Research Foundation. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.